Literature DB >> 18581271

Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma.

Hüseyin K Türköz1, Hülya Oksüz, Ziya Yurdakul, Deniz Ozcan.   

Abstract

Galectin-3 plays important roles in cell adhesion, cell proliferation, apoptosis, neoplastic transformation, and metastasis. Galectin-3 expression has been evaluated in various malignant neoplasms to determine its effectiveness in differential diagnosis from benign lesions and its effects on carcinogenesis. There are few and somewhat controversial results regarding its changes through cancer progression in thyroid malignancies. We studied the presence of galectin-3 expression immunohistochemically and its relation with tumor invasiveness and lymph node metastasis in 89 cases of papillary carcinoma of the thyroid. Galectin overexpression was less frequent in cases with lymph node metastases compared with cases without lymph node metastasis (P = 0.001). Metastatic foci in lymph nodes showed a lower degree of galectin-3 overexpression than their primary lesions (P = 0.001). Degree of galectin-3 overexpression was also lower in larger tumors (P = 0.009). Additionally, a decreased level of galectin-3 overexpression was observed at the invasive edges of the tumors (P = 0.001). Galectin-3 overexpression is more profound in early stages of papillary carcinoma, and its expression intensity decreases during tumor progression. This finding is consistent with roles for galectin-3 in cell adhesion to other tumor cells and the matrix.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18581271     DOI: 10.1007/s12022-008-9033-3

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  21 in total

Review 1.  Galectin-3 as a multifunctional protein.

Authors:  Anna Krześlak; Anna Lipińska
Journal:  Cell Mol Biol Lett       Date:  2004       Impact factor: 5.787

2.  Decreased expression of galectin-3 is associated with progression of human breast cancer.

Authors:  V Castronovo; F A Van Den Brûle; P Jackers; N Clausse; F T Liu; C Gillet; M E Sobel
Journal:  J Pathol       Date:  1996-05       Impact factor: 7.996

3.  Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size.

Authors:  Dubravka S Cvejic; Svetlana B Savin; Ivana M Petrovic; Ivan R Paunovic; Svetislav B Tatic; Marija J Havelka
Journal:  Head Neck       Date:  2005-12       Impact factor: 3.147

4.  Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation.

Authors:  K Kawachi; Y Matsushita; S Yonezawa; S Nakano; K Shirao; S Natsugoe; K Sueyoshi; T Aikou; E Sato
Journal:  Hum Pathol       Date:  2000-04       Impact factor: 3.466

5.  Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade.

Authors:  H Idikio
Journal:  Int J Oncol       Date:  1998-06       Impact factor: 5.650

6.  Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells.

Authors:  T Yoshii; H Inohara; Y Takenaka; Y Honjo; S Akahani; T Nomura; A Raz; T Kubo
Journal:  Int J Oncol       Date:  2001-04       Impact factor: 5.650

7.  Involvement of galectin-3 expression in colorectal cancer progression and metastasis.

Authors:  M Nakamura; H Inufusa; T Adachi; M Aga; M Kurimoto; Y Nakatani; T Wakano; A Nakajima; J I Hida; M Miyake; K Shindo; M Yasutomi
Journal:  Int J Oncol       Date:  1999-07       Impact factor: 5.650

8.  Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide.

Authors:  Young K Song; Timothy R Billiar; Yong J Lee
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

9.  Coexistent anaplastic and differentiated thyroid carcinoma: an immunohistochemical study.

Authors:  Yatsuki Aratake; Hajime Nomura; Tomio Kotani; Kosuke Marutsuka; Kaoru Kobayashi; Kanji Kuma; Akira Miyauchi; Akihiko Okayama; Kazuo Tamura
Journal:  Am J Clin Pathol       Date:  2006-03       Impact factor: 2.493

10.  The investigation of galectin-3 in diseases of the thyroid gland.

Authors:  Rita Beáta Kovács; János Földes; Gábor Winkler; Miklós Bodó; Zoltán Sápi
Journal:  Eur J Endocrinol       Date:  2003-11       Impact factor: 6.664

View more
  12 in total

1.  Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of β-catenin in gastric cancer.

Authors:  Seok-Jun Kim; Ji-Young Shin; Teak-Chin Cheong; Il-Ju Choi; Yeon Su Lee; Seok Hee Park; Kyung-Hee Chun
Journal:  Clin Exp Metastasis       Date:  2011-07-13       Impact factor: 5.150

2.  Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.

Authors:  Figen Barut; Nilufer Onak Kandemir; Sibel Bektas; Burak Bahadir; Sevinc Keser; Sukru Oguz Ozdamar
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

3.  Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.

Authors:  Sonja A Selemetjev; Svetlana B Savin; Ivan R Paunovic; Svetislav B Tatic; Dubravka Cvejic
Journal:  Wien Klin Wochenschr       Date:  2014-12-04       Impact factor: 1.704

4.  Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide.

Authors:  Jessica R Newton-Northup; Marie T Dickerson; Lixin Ma; Cynthia L Besch-Williford; Susan L Deutscher
Journal:  Clin Exp Metastasis       Date:  2012-08-01       Impact factor: 5.150

5.  Expression profiling of cancer-related galectins in acute myeloid leukemia.

Authors:  Asmaa A El Leithy; Reham Helwa; Magda M Assem; Nagwa H A Hassan
Journal:  Tumour Biol       Date:  2015-05-09

6.  THE ASSOCIATION BETWEEN LYMPH NODE METASTASIS AND MOLECULAR MARKERS IN DIFFERENTIATED THYROID CANCER.

Authors:  B I Aydoğan; C C Ersöz; S D Sak; S Güllü
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jan-Mar       Impact factor: 0.877

7.  Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment.

Authors:  Y Wang; P Nangia-Makker; V Balan; V Hogan; A Raz
Journal:  Cell Death Dis       Date:  2010-11-18       Impact factor: 8.469

8.  Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.

Authors:  Qingbin Song; Deguang Wang; Yi Lou; Changsi Li; Changqing Fang; Xiangmin He; Jianhua Li
Journal:  Diagn Pathol       Date:  2011-12-21       Impact factor: 2.644

9.  Serum biomarkers of papillary thyroid cancer.

Authors:  Fawaz M Makki; S Mark Taylor; Ali Shahnavaz; Andrew Leslie; Jeffrey Gallant; Susan Douglas; Evelyn Teh; Jonathan Trites; Martin Bullock; Karen Inglis; Devanand M Pinto; Robert D Hart
Journal:  J Otolaryngol Head Neck Surg       Date:  2013-02-07

10.  Absent CD56 expression in papillary thyroid carcinoma: A finding of potential diagnostic value in problematic cases of thyroid pathology.

Authors:  Mozhgan Mokhtari; Mehdi Eftekhari; Reza Tahririan
Journal:  J Res Med Sci       Date:  2013-12       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.